Category Archives: Research

Patient Focused Drug Development

Posted on October 25, 2012 by Jennie Spotila

The FDA hosted a public meeting this morning to discuss the Patient Focused Drug Development (PFDD) initiative. The meeting was available via webcast, and a transcript will be published on the FDA website. CFS is on the list of candidate … Continue reading →

Posted in Advocacy, Research | Tagged , , , , , , , | 7 Comments

Mary Dimmock’s Comments to the FDA

Posted on October 25, 2012 by Jennie Spotila

Mary Dimmock presented a shortened version of these comments at the FDA meeting today on the Patient Focused Drug Development initiative. She has kindly given me permission to post her comments in full here. My name is Mary Dimmock and … Continue reading →

Posted in Advocacy, Research | Tagged , , , , , , , , , , | 3 Comments

Those Lipkin Samples

Posted on September 22, 2012 by Jennie Spotila

You may recall from my post on the Lipkin study that Dr. Lipkin talked about the sample cohort at the press conference on September 18th. Dr. Lipkin said that the samples would be available for other investigators and that applications … Continue reading →

Posted in Research | Tagged , , , , , , , , , , , | 4 Comments

Stick a Fork In It

Posted on September 18, 2012 by Jennie Spotila

After three years of controversy about the purported association between CFS and XMRV, and after two years of waiting for the definitive Lipkin study to be finished (full text of the paper is here), we have our answer. Stick a … Continue reading →

Posted in Commentary, Research | Tagged , , , , , , , , , , , , | 13 Comments

The News on XMRV

Posted on September 18, 2012 by Jennie Spotila

I am going to refrain from any comment on the XMRV study results announced today until I have had a chance to read the paper, listen to the press conference, and think about the whole thing for a few hours. … Continue reading →

Posted in Research | Tagged , , , , , , , , , | 3 Comments

Will FDA Step Up?

Posted on September 13, 2012 by Jennie Spotila

The Federal Drug Administration held a conference call today to speak with CFS patients, advocacy groups and other interested parties. This is the first time in the history of this disease that FDA has communicated with the patient community in … Continue reading →

Posted in Advocacy, Research | Tagged , , , , , , , | 25 Comments

NIH Funding and the XMRV Effect

Posted on July 31, 2012 by Jennie Spotila

The largest pool of money available for investigator-initiated CFS research grants is the NIH. Although miniscule relative to other areas of research, $6 million a year is the largest annual research investment in CFS from any source. Given the significance … Continue reading →

Posted in Research | Tagged , , , , , , , , , | 14 Comments

2011 NIH Spending on CFS Studies

Posted on July 16, 2012 by Jennie Spotila

At the June 2012 CFS Advisory Committee meeting, Dr. Susan Maier from the NIH Office of Research on Women’s Health reported that NIH funding of CFS research in 2011 totaled $6.3 million. In the past, advocates have questioned whether studies … Continue reading →

Posted in Research | Tagged , , , , , , , , , , , , , | 3 Comments

XMRumorsV

Posted on June 15, 2012 by Jennie Spotila

Rumors about the Lipkin study are flying fast and furious these days. We’ve been hearing for months that the study results would be made public this year, but “news” of specific dates has kicked things into a frenzy. In April, … Continue reading →

Posted in Research | Tagged , , , , , , | 7 Comments

Abstract Risk

Posted on June 6, 2012 by Jennie Spotila

I posted about the cancer and CFS study last week based on the abstract only. Now I have a copy of the full paper, and there is much more to discuss. Dr. Suzanne Vernon also wrote about the study, so … Continue reading →

Posted in Research | Tagged , , , , , , , , , | 4 Comments